易瑞沙治疗化疗失败的晚期非小细胞肺癌疗效分析  

Treatment with Iressa in advanced non-small-cell lung cancer patients who failed in previous chemotherapy——10 cases report

作　　者：王志新[1] 胡义德[1] 金彦青[1] 徐先琼[1] 谢启超[1] 段玉忠[1] 陈正堂[1] 

机构地区：[1]第三军医大学新桥医院全军肿瘤研究所,重庆400037

出　　处：《中国肿瘤临床与康复》2008年第2期168-170,173,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨易瑞沙(Irssa)单药治疗化疗失败的晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法经TP和NP/GP方案化疗失败的Ⅳ期NSCLC患者10例,口服易瑞沙250 mg,1次/d,至病情进展或出现严重不良反应。结果10例患者中CR 3例,PR 5例,NC 2例,有效率80.0%。有效者均不吸烟,5例为女性,3例男性均为肺泡细胞癌。不良反应:7例有皮肤改变表现(脱屑、痤疮),1例有轻度腹泻。1例CR和1例PR患者在服药14个月和10个月后出现复发和新病灶。结论易瑞沙能有效缓解晚期化疗失败的女性NSCLC及不吸烟的男性肺泡细胞癌患者的病情。长期服用易瑞沙的患者可能出现获得性耐药。Objective To evaluate the efficacy and adverse effects of single-drug Iressa in treatment of non-small-cell lung cancer（NSCLC） patients who failed in previous chemotherapy. Methods Ten stage- Ⅳ NSCLC patients were included in the trial. All patients had failed in the TP,NP or GP regimen treatment. The therapy consisted of Iressa 250 mg orally once daily until the disease progression and appearance of serious side effect. Results The overall response rate was 80.0% （8/10）. Three patients achieved complete response （CR） , five partial response （PR） and two stable disease （SD）. All of the eight patients （ five female） with CR and PR were non-smoklng persons. Three male patients had bronchioloalveolar carcinoma. Adverse effects： seven patients had acne, skin rash and desquamation （70.0%）, one patient had mild diarrhea （10.0%）. One CR patient had relapse and one PR patient had new lesion offer treatment for 14 and 10 months respectively. Conclusion Iressa can produce dramatic clinical response in female and non-smoking male advanced NSCLC patients who failed in previous chemotherapy, but long-time treatment may result in acquired drug resistance.

关 键 词：肺肿瘤 易瑞沙 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]